

## **AMENDMENTS**

### ***Please amend the Claims as follows:***

1. (Currently amended) An immunological reagent produced by introducing a cell expressing a heterologous P-glycoprotein into an animal syngeneic with the species from which the cell was derived, wherein the heterologous P-glycoprotein is in a biochemical conformation adopted in the presence of Pgp-mediated transport substrates or ATP depleting agents, and producing immune cells in the animal expressing said reagent specific for human P-glycoprotein in said biochemical conformation.

2. (Original) An immunological reagent according to claim 1 that is a monoclonal antibody.

3. (Currently amended) An immunological reagent according to claim 1, wherein the heterologous P-glycoprotein comprises a mutant human P-glycoprotein having an ATPase-specific active site in each half of the human Pgp molecule comprising an amino acid residue at position 433 and 1076 of the Pgp amino acid sequence that is an amino acid residue other than lysine.

4. (Currently amended) An immunological reagent according to claim 1, wherein the heterologous P-glycoprotein ~~comprises~~ has an the amino acid sequence identified as ~~Seq. I.D. No. 4~~ SEQ ID NO:2.

5. (Currently amended) An immunological reagent according to claim 1, wherein the heterologous P-glycoprotein expressing syngeneic cell expresses a mutant human P-glycoprotein wherein each of the ATPase-specific active site lysine residues of the protein are independently substituted with methionine.

6. (Currently amended) An immunological reagent according to claim 1, wherein the reagent is specific for human P-glycoprotein in a biochemical conformation adopted in the presence of an ATP depleting agent.